Bone

Patient Monitoring (I9)

Overview In this lesson we will discuss the role of patient monitoring during radiolingand therapy of bone metastases. In particular, the first part will focus on 223Radium dichloride (223RaCl) therapy for castration resistant prostate cancer (CRPC) patients while in the second we will discuss 177Lu-prostate specific membrane antigen (177Lu-PSMA) treatment in metastatic CRPC subjects. For

Patient Monitoring (I9) Read More »

Schedule and Regimens and Dose Adjustment (I6)

Overview In this lesson, general requirements for administration of radioligand therapy for bone metastases are discussed. Details are provided on the schedule, regimens and dose adjustments of 89Sr-chloride, 153Sm-lexidronam and 223Ra-dichloride treatment in patients with osteoblastic bone metastases, including information on patient preparation, treatment administration, post-therapy imaging and radiation safety measures.

Schedule and Regimens and Dose Adjustment (I6) Read More »

RLT when, why, how (I5)

Overview In this lesson, the general application of radioligand therapy in patients with bone metastases is discussed. Furthermore, details are provided regarding the indications, contra-indications and mechanism of action of 89Sr-chloride, 153Sm-lexidronam and 223Ra-dichloride treatment in patients with osteoblastic bone metastases.

RLT when, why, how (I5) Read More »